PATENT

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/155, 31/12 — A1

(11) International Publication Number: WO 94/12164

(43) International Publication Date: 9 June 1994 (09.06.94)

(21) International Application Number: PCT/GB93/02425

(22) International Filing Date: 25 November 1993 (25.11.93)

(30) Priority Data:
9224739.4 26 November 1992 (26.11.92) GB

(71) Applicant *(for all designated States except US)*: THE WELLCOME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: GUTTERIDGE, Winston, Edward [GB/GB]; Langley Court, Beckenham, Kent BR3 3BS (GB). HUTCHINSON, David, Brian, Ashton [GB/GB]; Langley Court, Beckenham, Kent BR3 3BS (GB). LATTER, Victoria, Susan [GB/GB]; Langley Court, Beckenham, Kent BR3 3BS (GB). PUDNEY, Mary [GB/GB]; Langley Court, Beckenham, Kent BR3 3BS (GB).

(74) Agent: ROLLINS, Anthony, John; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB).

(81) Designated States: AU, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, NO, NZ, PL, RO, RU, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
*With international search report.*

950748 FI

(54) Title: COMBINATION OF ATOVAQUONE WITH PROGUANIL FOR THE TREATMENT OF PROTOZOAL INFECTIONS

(57) Abstract

The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections, such as protozoal parasitic infections, e.g. malaria and toxoplasmosis, and infections caused by P.carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.